Biotech Startups

TheraDep develops nanoscale plasma coating technology that bonds pharmaceuticals, biologics, and polymers onto surfaces such as metals, plastics, ceramics, and composites at room temperature. Its process targets manufacturers in the labware and medical device markets, offering custom coating solutions that integrate into existing production lines.

3 investors

Theremia develops statistical methods for analyzing clinical trial outcomes, including a Nearest Neighbor Pairing approach to improve Win Ratio estimation of individual causal treatment effects in heterogeneous patient populations. Its work targets precision medicine and drug benefit-risk assessment, with attention to adverse drug reactions and CNS treatments.

3 investors

3 investors

Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases. It is built around scientific advisors and leadership with expertise in ion channel biology and biophysics.

3 investors

Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution. Its drug discovery platform draws on single-cell genomics and AI for biology.

3 investors

Transcriptic operates a robotic cloud laboratory platform for on-demand life science research, letting scientists design and run reproducible experiments remotely. It serves pharmaceutical and biotech companies working in drug discovery and synthetic biology, offering both on-premise deployment and managed bioassay services through a web interface.

3 investors

Transfyr builds a sensor stack and multimodal AI models that record and analyze the physical execution of scientific experiments, capturing details that distinguish success from failure. Its technology serves scientists and labs to reduce variance, support automation, enable tech transfer, and improve training.

3 investors

Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.

3 investors

Transition Metal Solutions applies microbial and biochemical methods to enhance copper extraction from low-grade ores, enabling more efficient recovery with reduced environmental impact for mining operations. The company works within existing mining infrastructure rather than replacing it, targeting the growing copper demand from the energy transition.

3 investors

Trials.ai builds agentic AI technology for clinical trial design, digitizing and automating study creation while offering AI-powered recommendations on endpoints, eligibility criteria, schedules, and patient populations. Its products, powered by a clinical study ontology and data graph, serve life sciences and clinical development teams.

3 investors

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.

3 investors

Trinity Guardion makes the Soteria Bed Barrier, an FDA-cleared, launderable and reusable physical barrier that protects hospital beds and mattresses from patient soiling to reduce Healthcare-Acquired Infections. It sells to healthcare facilities for use on beds, warmers, and incubators from major manufacturers, aiming to cut mattress reprocessing time and improve patient safety.

3 investors

Trojan Bio develops bispecific antibodies for cancer immunotherapy, using an AI-driven platform that pairs a cancer-targeting module with a viral immunity activation module to mark tumor cells as virally infected and recruit anti-viral immune responses. Its approach is designed to be switchable across different tumor types.

3 investors

Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies. Its lead program is a CDK2 inhibitor (CDK2i), with plans to expand into additional kinase targets across the human kinome.

3 investors

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers. The company operates in the biotech/pharmaceutical drug development space.

3 investors

uFraction8 develops microfluidics-based filtration systems for bioprocessing applications, enabling energy-efficient harvesting and processing of microbial cell cultures for biopharmaceutical manufacturers. The technology targets industrial-scale bio-manufacturing and is positioned to replace conventional filters and centrifuges in cell culture processing.

3 investors

uLab Systems builds digital orthodontics tools, including software (uDesign, uAssist) and uSmile clear aligners manufactured in the USA, for dental professionals and orthodontic practices. The company offers a platform for personalized orthodontic care aimed at improving treatment outcomes and practice efficiency.

3 investors

Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases. The company emphasizes a culture of generosity, curiosity, and inclusion among its team members.

3 investors

uMed provides data and insights infrastructure to accelerate the development and delivery of new medicines by addressing evidence gaps across the therapy lifecycle. The company enables access to clinical research data and patient insights for pharmaceutical companies, researchers, and healthcare institutions developing new treatments.

3 investors

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process. The company operates its own in-house manufacturing to supply its therapeutics.

3 investors

Unchained Labs builds instruments for lipid nanoparticle and other nanomedicine production, spanning R&D formulation screening through GMP-compliant clinical manufacturing. Its Sunny Suite uses a consistent mixing process to help pharmaceutical and biotech developers transfer nanoparticle production from lab scale to liter-scale GMP output.

3 investors

Uncommon Bio has sold its cultivated meat platform to Vow and is now focusing on SymphoRNA, leveraging its nucleic acid delivery technology.

3 investors

Unibaio develops TurboCharge, a bioactive carrier platform that makes existing crop protection products more effective, allowing lower chemical use while improving field performance for farmers. The technology draws on biological and materials science to deliver agrochemicals and biologicals across a range of crops.

3 investors

Union.ai provides a workflow orchestration platform, built on Flyte, that lets biotech and life-sciences teams write and run computational pipelines in pure Python with per-task container images, mixed CPU/GPU compute, and input-hash caching. It targets scientific workloads such as protein design, folding, docking, and screening, with artifact versioning and immutable execution records for reproducibility and regulated/clinical auditability.

3 investors